Clinical Trial Update: I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW). [Phase 2]

View source ↗

Summary

Phase 2 ARROW trial comparing I-131-1095 radioligand plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer that progres…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• I-131-1095 radioligand
• Xtandi (enzalutamide)

Snippet

Sponsor: Progenics Pharmaceuticals, Inc. | Conditions: Metastatic Prostate Cancer, Castration-resistant Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2025-10-14